Asset Details
Do you wish to reserve the book?
Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer
Do you wish to request the book?
Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer
2018
Overview
Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases. Small cell lung cancer is characterized by frequent relapse, and current treatments lack tumor specificity. Arginine is a non‐essential amino acid for human normal cells but critical to some tumor cells that cannot synthesize arginine. Therefore, arginine deprivation has become a potential therapeutic option for selected tumors. BCT‐100 is a pegylated arginase that has documented anticancer activity in arginine auxotrophic tumors, such as melanoma, hepatocellular carcinoma, and acute myeloid leukemia. One of the resistance mechanisms to arginase treatment is overexpression of argininosuccinate synthetase (ASS1) and ornithine transcarbamylase (OTC), two important enzymes in the urea cycle. We selected 9 SCLC and 1 non‐small cell lung carcinoma cell lines to determine the growth inhibition effects of BCT‐100 and established that cell lines with low expression of ASS1 and OTC are relatively sensitive to BCT‐100 treatment. Knocking down OTC in a H841 cell line could potentiate its sensitivity to BCT‐100 treatment. Arginine concentration was sharply decreased, accompanied by apoptosis through oxidative stress as well as G1 cell cycle arrest. In addition, BCT‐100 showed an anticancer effect on H446 and H510A xenograft models by lowering arginine levels and inducing apoptosis. BCT‐100 is one type of pegylated recombinant human arginase. BCT‐100 showed an anticancer effect against small cell lung cancer through oxidative stress, apoptosis, and cell cycle arrest.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Animals
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - pharmacology
/ Arginase
/ Arginase - administration & dosage
/ Arginine
/ BCT‐100
/ Cell Proliferation - drug effects
/ Cell Survival - drug effects
/ Enzymes
/ Gene Expression Regulation, Neoplastic - drug effects
/ Humans
/ Kinases
/ Leukemia
/ Lung Neoplasms - drug therapy
/ Melanoma
/ Mice
/ Non-small cell lung carcinoma
/ Original
/ Proteins
/ Recombinant Proteins - administration & dosage
/ Recombinant Proteins - pharmacology
/ Small Cell Lung Carcinoma - drug therapy
/ Small Cell Lung Carcinoma - metabolism
/ Tumors
/ Urea
